1. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
- Author
-
Gallant, Joel E., DeJesus, Edwin, Arribas, Jose R., Pozniak, Anton L., Gazzard Brian, Compo, Rafael E., Toole, John J., Biao Lu, Cheng, Andrew K., McColl, Damian, Chuck, Steven, and Enejosa, Jeffrey
- Subjects
Efavirenz (Medication) -- Comparative analysis ,Efavirenz (Medication) -- Dosage and administration ,Tenofovir -- Dosage and administration ,Tenofovir -- Comparative analysis ,Lamivudine -- Dosage and administration ,Lamivudine -- Comparative analysis ,HIV infection -- Drug therapy ,Clinical trials - Abstract
A prospective, randomized, multicenter noninferiority study comparing the regiments of tenofovir DF, emtricitabine and efavirenz and a fixed dose of zidovudine and lamivudine plus efavirenz were conducted. Results revealed that the combination of tenofovir DF and emtricitabine plus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.
- Published
- 2006